Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Drug Use Investigation of LENVIMA 4 mg Capsules - A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Patients With Unresectable Hepatocellular Carcinoma

NCT03663114 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03663114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03663114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Drug Use Investigation of LENVIMA 4 mg Capsules - A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
Eisai Inc.
Phase
Observational
Overall status
Completed
Start date
July 2, 2018
Completion date
February 20, 2020
Enrollment
713 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular